Brief: Olema Pharmaceuticals QTRLY Net Loss Per Share $0.82
09/08/2022 23:03
Aug 9 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY REPORTS SECOND QUARTER 2022 FINANCIAL
RESULTS AND
PROVIDES CORPORATE UPDATE
* QTRLY NET LOSS PER SHARE $0.82
* Q2 EARNINGS PER SHARE VIEW $-0.64 -- REFINITIV IBES DATA
* ANTICIPATES THAT THIS BALANCE WILL BE SUFFICIENT TO FUND
OPERATIONS INTO SECOND HALF OF 2024
Source text for Eikon: ID:nGNX3tDV1L
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs